

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6549278

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PEROSPHERE PHARMACEUTICALS, INC.	02/11/2021
RECEIVING PARTY DATA	
Name:	COVIS PHARMA GMBH
Street Address:	GRAUFENAUWEG 12
City:	ZUG
State/Country:	SWITZERLAND
Postal Code:	6300
PROPERTY NUMBERS Total: 9	
Property Type	Number
Patent Number:	9956287
Patent Number:	9999690
Patent Number:	9522892
Patent Number:	9877961
Application Number:	15726497
Application Number:	61564559
Application Number:	61614292
Application Number:	61641698
Application Number:	61666291
CORRESPONDENCE DATA	
Fax Number:	(703)836-6621
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	7038386522
Email:	deborah.thodos@bipc.com
Correspondent Name:	DEBORAH D THODOS
Address Line 1:	1737 KING STREET
Address Line 2:	SUITE 500
Address Line 4:	ALEXANDRIA, VIRGINIA 22314
NAME OF SUBMITTER:	DEBORAH D. THODOS
SIGNATURE:	/Deborah D. Thodos/

PATENT

DATE SIGNED:	02/12/2021
---------------------	------------

Total Attachments: 7

source=Patent_Assignment_3_Perosphere_Pharmaceuticals_Inc 4812-4902-3708 v.1#page1.tif

source=Patent_Assignment_3_Perosphere_Pharmaceuticals_Inc 4812-4902-3708 v.1#page2.tif

source=Patent_Assignment_3_Perosphere_Pharmaceuticals_Inc 4812-4902-3708 v.1#page3.tif

source=Patent_Assignment_3_Perosphere_Pharmaceuticals_Inc 4812-4902-3708 v.1#page4.tif

source=Patent_Assignment_3_Perosphere_Pharmaceuticals_Inc 4812-4902-3708 v.1#page5.tif

source=Patent_Assignment_3_Perosphere_Pharmaceuticals_Inc 4812-4902-3708 v.1#page6.tif

source=Patent_Assignment_3_Perosphere_Pharmaceuticals_Inc 4812-4902-3708 v.1#page7.tif

ASSIGNMENT

THIS ASSIGNMENT, by **PEROSPHERE PHARMACEUTICALS, INC.**, having a principal place of business at **20 KENOSIA AVENUE, DANBURY, CONNECTICUT 06810** (hereinafter referred to as "the Assignor"), respectively, witnesseth:

WHEREAS, the Assignor is the owner of the entire right, title and interest in and to the below-identified Letters Patent and applications for Letters Patent included in Table 1, attached hereto.

AND WHEREAS, **COVIS PHARMA GmbH**, a limited liability company (Gesellschaft mit beschränkter Haftung) duly organized under and pursuant to the laws of **SWITZERLAND** and having a principal place of business at **GRAUFENAUWEG 12, 6300 ZUG, SWITZERLAND**, registered with the commercial register of the Canton of Zug under number CHE 403-495-189 (hereinafter referred to as "the Assignee"), is desirous of acquiring, and does hereby acquire, the entire right, title, and interest in and to said patents and patent applications.

AND WHEREAS, this assignment has an Effective Date of November 16, 2020; except that, should a jurisdiction not permit an assignment having an earlier effective date than the date of signature by the parties, then in that jurisdiction this assignment shall have an Effective Date the same as the date that the later of the Assignor or Assignee applies its signature.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns the entire right, title, and interest in and to the above-mentioned Letters Patent and applications for Letters Patent, and reissues and extensions of said Letters Patent, and all rights of priority associated therewith, the same to be held and enjoyed by the Assignee, for its own use and benefit and the use and benefit of its successors, legal representatives, and assigns, to the full end of the term of said Letters Patent as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, the Assignor is the lawful owner of the entire right, title, and interest in said Letters Patent and applications for Letters Patent, and that the same are unencumbered, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth;


AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns that the Assignor will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with any of said Letters Patent or application for Letters Patent, including interference or inter partes review proceedings, or any reissue or extension of any of said Letters Patent, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the maintenance, enforcement, and defense of said Letters Patent, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

AND the Assignor hereby requests the Commissioner of Patents or other requisite official to issue any said Letters Patent to the Assignee.

[SIGNATURE PAGE FOLLOWS]

PEROSPHERE PHARMACUETICALS, INC.

DATE: 2/11/2021

By:  _____
DocuSigned by:
0EA7D008DA304D9...


Name: Francesco Tallarico

Title: Secretary

Accepted by:

COVIS PHARMA GmbH

DATE: 2/11/2021

By:  _____
DocuSigned by:
44440DA0A19E4C6...

Name: Fabio Fazio

Title: SVP

TABLE 1

Jurisdiction	Patent Number	Patent Application Number	Title
United States	9,956,287	14/766,347	Stable glucagon formulations
United States	9,999,690	14/534,474	Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds
United States	9,522,892	13/688,442	Anticoagulant reversal agents
United States	9,877,961	15/348,348	Anticoagulant reversal agents
United States	Not yet issued	15/726,497	Anticoagulant reversal agents
United States	N/A	61/564,559	Anticoagulant reversal agents
United States	N/A	61/614,292	Anticoagulant reversal agents
United States	N/A	61/641,698	Anticoagulant reversal agents
United States	N/A	61/666,291	Anticoagulant reversal agents
World Intellectual Property Organization	N/A	PCT/US2012/066938 Published as: WO 2013/082210 A1	Anticoagulant reversal agents
Albania (AL)	12806229.6	2785700	Anticoagulant reversal agents
African Regional Intellectual Property Organization (ARIPO)	AP/P/2014/007662	AP4295	Anticoagulant reversal agents
Argentina (AR)	2012P0104474	AR089020	Anticoagulant reversal agents
Austria (AT)	12806229.6	2785700	Anticoagulant reversal agents
Australia (AU)	2012345975	20120345975	Anticoagulant reversal agents

Bosnia & Herzegovina (BA)	2785700	12806229.6	Anticoagulant reversal agents
Belgium (BE)	2785700	12806229.6	Anticoagulant reversal agents
Bulgaria (BG)	2785700	12806229.6	Anticoagulant reversal agents
Brazil (BR)	Not yet issued	BR112014128928	Anticoagulant reversal agents
Canada (CA)	2856540	2856540	Anticoagulant reversal agents
Switzerland (CH)	2785700	12806229.6	Anticoagulant reversal agents
Chile (CL)	57113	2014-01399	Anticoagulant reversal agents
China (CN)	ZL201280060950.2	201280060950.2	Anticoagulant reversal agents
Colombia (CO)	6350	14137450	Anticoagulant reversal agents
Costa Rica (CR)	3939	2014-0310	Anticoagulant reversal agents
Cyprus (CY)	2785700	12806229.6	Anticoagulant reversal agents
Czech Republic (CZ)	2785700	12806229.6	Anticoagulant reversal agents
Germany (DE)	2785700	12806229.6	Anticoagulant reversal agents
Denmark (DK)	2785700	12806229.6	Anticoagulant reversal agents
Eurasian Patent Organization (EA)	027603	201490823	Anticoagulant reversal agents
Ecuador (EC)	Official Gazette No. 605	IEPI-2014-6696	Anticoagulant reversal agents
Estonia (EE)	2785700	12806229.6	Anticoagulant reversal agents
Egypt (EG)	Not yet issued	PCT867/2014	Anticoagulant reversal agents
European Patent Office (EP)	2785700	12806229.6	Anticoagulant reversal agents
Spain (ES)	2785700	12806229.6	Anticoagulant reversal agents

Finland (FI)	2785700	12806229.6	Anticoagulant reversal agents
France (FR)	2785700	12806229.6	Anticoagulant reversal agents
United Kingdom (GB)	2785700	12806229.6	Anticoagulant reversal agents
Gulf Co-Operation Council	GC0009662	22926	Anticoagulant reversal agents
Greece (GR)	2785700	12806229.6	Anticoagulant reversal agents
Hong Kong (HK)	HK1202858	15103329.9	Anticoagulant reversal agents
Croatia (HR)	2785700	12806229.6	Anticoagulant reversal agents
Hungary (HU)	2785700	12806229.6	Anticoagulant reversal agents
Indonesia (ID)	IDP000052624	P00201403820	Anticoagulant reversal agents
Ireland (IE)	2785700	12806229.6	Anticoagulant reversal agents
Israel (IL)	232788	232788	Anticoagulant reversal agents
India (IN)	Not yet issued	5190/DELNP/2014	Anticoagulant reversal agents
Iceland (IS)	2785700	12806229.6	Anticoagulant reversal agents
Italy (IT)	2785700	12806229.6	Anticoagulant reversal agents
Japan (JP)	6134731	2014-544857	Anticoagulant reversal agents
Republic of Korea (KR)	10-1892330	2014-7016304	Anticoagulant reversal agents
Liechtenstein (LI)	2785700	12806229.6	Anticoagulant reversal agents
Lithuania (LT)	12806229.6	2785700	Anticoagulant reversal agents
Luxembourg (LU)	2785700	12806229.6	Anticoagulant reversal agents
Latvia (LV)	2785700	12806229.6	Anticoagulant reversal agents

Monaco (MC)	2785700	12806229.6	Anticoagulant reversal agents
Montenegro (ME)	2785700	12806229.6	Anticoagulant reversal agents
Macedonia (MK)	2785700	12806229.6	Anticoagulant reversal agents
Malta (MT)	2785700	12806229.6	Anticoagulant reversal agents
Mexico (MX)	349514	MX/a/2014/006349	Anticoagulant reversal agents
Netherlands (NL)	2785700	12806229.6	Anticoagulant reversal agents
Norway (NO)	2785700	12806229.6	Anticoagulant reversal agents
New Zealand (NZ)	625337	625337	Anticoagulant reversal agents
African Intellectual Property Organization (OAPI)	16905	1201400228	Anticoagulant reversal agents
Peru (PE)	9091	763	Anticoagulant reversal agents
Philippines (PL)	1-2014-501176	1-2014-501176	Anticoagulant reversal agents
Poland (PL)	2785700	12806229.6	Anticoagulant reversal agents
Portugal (PT)	2785700	12806229.6	Anticoagulant reversal agents
Romania (RO)	2785700	12806229.6	Anticoagulant reversal agents
Serbia (RS)	2785700	12806229.6	Anticoagulant reversal agents
Sweden (SE)	2785700	12806229.6	Anticoagulant reversal agents
Singapore (SG)	11201402713W	11201402713W	Anticoagulant reversal agents
Slovenia (SI)	2785700	12806229.6	Anticoagulant reversal agents
Slovakia (SK)	2785700	12806229.6	Anticoagulant reversal agents
San Marino (SM)	2785700	12806229.6	Anticoagulant reversal

			agents
Thailand (TH)	Not yet issued	1401002981	Anticoagulant reversal agents
Turkey (TR)	2785700	12806229.6	Anticoagulant reversal agents
Ukraine (UA)	116336	a201404997	Anticoagulant reversal agents
Vietnam (VN)	Not yet issued	1-2014-02058	Anticoagulant reversal agents
South Africa (ZA)	2014/04793	2014/04793	Anticoagulant reversal agents